Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23810206 | 0.81 | KDM4E (0.41) | KDM4EKDM4CNPC1RAB9AZDHHC20 | |
| SCHEMBL22150190 | 0.78 | SMN1; SMN2 (0.41) | ZDHHC20ZDHHC2HDAC1 | |
| SCHEMBL22149742 | 0.77 | HDAC3 (0.42) | ZDHHC20ZDHHC2TGM2HDAC1 | |
| SCHEMBL25070736 | 0.77 | KDM4E (0.43) | KDM4EKDM4CNPC1RAB9AEPHX2 | |
| SCHEMBL28948985 | 0.77 | HPGDS (0.59) | KDM4ETGM2EPHX2HDAC1 | |
| SCHEMBL23810139 | 0.77 | SMN1; SMN2 (0.42) | KDM4EZDHHC20ZDHHC2TGM2HDAC1 | |
| SCHEMBL30153375 | 0.77 | HPGDS (0.59) | KDM4ETGM2EPHX2HDAC1 | |
| SCHEMBL18022784 | 0.74 | KDM4E (0.50) | KDM4EKDM4CEPHX2 | |
| SCHEMBL30153214 | 0.74 | HPGDS (0.59) | KDM4EKDM4CRAB9AEPHX2ALOX15 | |
| SCHEMBL28948987 | 0.74 | HPGDS (0.59) | KDM4EKDM4CRAB9AEPHX2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284609-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| WO-2020126598-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284609-A1 | HETEROCYCLIC AZIDE UNITS AND THEIR USE IN POLYMER COATINGS | POLL, PCNA, DNMT3A | KDM4E 3663/4885KDM4C 1062/4885NPC1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.